Skip to content
Screener

Bioventus BVS Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$132.1MBeat by $2.2M
EPS$0.15Beat by $0.06
Revenue estimate$129.9M
EPS estimate$0.09

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$149.5M
EPS estimate$0.17

Financials

Q1 2026

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation & ratios

Valuation

as of 03/28/26
See full
Market cap$615.07M+1.6%
Enterprise value$867.64M-8.5%
P/E21.6×—
P/S1.1×0.0×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Segments

By product

See full
Pain Treatments$63.4M+7.7%
Surgical Solutions$48.0M+6.2%
Restorative Therapies$20.6M+4.6%

By segment

See full
U.S. Segment$116.4M+5.4%
International Segment$15.6M+17.1%

FAQ

When did Bioventus report Q1 2026 earnings?
Bioventus (BVS) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Bioventus's Q1 2026 revenue and EPS?
Bioventus reported revenue of $132.1M and eps of $0.15 for Q1 2026.
Did Bioventus beat estimates in Q1 2026?
Revenue beat the consensus estimate of $129.9M by $2.2M. EPS beat the consensus estimate of $0.09 by $0.06.
How did Bioventus's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.6% from $123.9M a year earlier and eps grew 87.5% from $0.08.
Where can I find Bioventus's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001665988-26-000026) and the 10-Q periodic report (0001665988-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.